We thus performed a 10-year (1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006) nationwide retrospective study to describe AIDS-related histoplasmosis during the HAART era in metropolitan France, a non-endemic country. We compared these recent cases to those recorded during the pre-HAART era (1985)(1986)(1987)(1988)(1989)(1990)(1991)(1992)(1993)(1994) to investigate the impact of HAART on the epidemiology, clinical manifestations, and prognosis of AIDS-related imported histoplasmosis.
INTRODUCTION Extrapulmonary infection caused by Histoplasma capsulatum var. capsulatum is an acquired immune deficiency syndrome (AIDS)-defining opportunistic infection.
1 This systemic fungal infection is endemic in certain areas of North and South America, Asia, and Africa. 2 It represented the first manifestation of human immunodeficiency virus (HIV) infection in up to 25% of AIDS patients in highly endemic areas before the availability of highly active anti-retroviral therapy (HAART). 3 AIDS-related histoplasmosis is almost always disseminated and mortality is high in the absence of accurate diagnosis and prompt appropriate antifungal treatment. 3, 4 Liposomal amphotericin B has proved superior to deoxycholate amphotericin B in reducing overall mortality and iatrogenic renal failure in the HIV infection context and is the recommended first-line therapy of severe cases. 5, 6 Retrospective 7, 8 and prospective 9, 10 studies from endemic areas have identified various prognostic factors. The impact of HAART on the epidemiology and outcome of histoplasmosis has not been extensively studied, even in endemic areas, and only a limited number of cases of immune reconstitution inflammatory syndrome (IRIS) cases have been reported in AIDS patients.
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Disseminated histoplasmosis can also be diagnosed in AIDS patients living in non-endemic area after acute exposure or delayed reactivation of a latent infection providing the patient had previously lived or traveled to a disease-endemic area. 2 Updated data on AIDS-related histoplasmosis in non-endemic areas are lacking. A recent review of the literature identified only 68 cases in Europe published during 12 and an epidemiologic survey reported 45 cases diagnosed in 10 countries in Europe during 1995-1999. infection parameters (date of diagnosis, CD4 cell count, and viral load at the time of histoplasmosis diagnosis, previous opportunistic infections, anti-retroviral therapy) and histoplasmosis characteristics (clinical presentation, diagnostic modalities, antifungal treatment and follow-up up to April 2008) .
Data from the pre-HAART cohort were obtained in 1995 by using the same questionnaire and methods and were reported in part in 1996 (Lortholary O and others, Abstract I174, 36th Interscience Conference on Chemotherapy and Antimicrobial Agents, New Orleans, LA, September 15-18, 1996) .
Definitions. Histoplasmosis was defined by isolation of H. capsulatum from any body site or by visualization of small ovoid (3-4 µm) intracellular yeasts compatible with H. capsulatum upon examination of tissue section or fluid pellet in a context compatible with the diagnosis.
Clinical pulmonary signs included cough, dyspnea, sputum, and hemoptysis. Mucocutaneous symptoms were defined as presence of any of skin ulceration, papule, pseudo-molluscum lesions, and/or pharyngeal ulceration. Neurologic signs were defined as presence of any of seizure, motor deficit, coma, meningitis. Histoplasmosis was considered as disseminated if at least two non-contiguous organs were involved.
Previously established criteria of severity were used 7, 10 and corresponded to the presence of at least one of the following: hypoalbuminemia (< 35 g/L), disseminated intra-vascular coagulation, lactate dehydrogenase levels > 2 times the upper limit of the reference range, creatinine concentration > 185 µM (2.1 mg/dL), systolic blood pressure < 90 mm of Hg, and hypoxemia (PaO 2 < 60 mm of Hg).
Amphotericin B treatment should have lasted at least 14 days to be considered for analysis. In case of successive therapy with deoxycholate amphotericin B and liposomal amphotericin B, only the formulation that had been received longer was considered for analysis. Maintenance therapy was considered as therapy that started three months after initiation of antifungal treatment. Relapse was defined as new onset of clinical signs with new isolation of H. capsulatum on culture or visualization of small ovoid (3-4 µm) intracellular yeasts upon examination of tissue section or fluid pellet. The existence of histoplasmosisrelated IRIS was systematically investigated using published criteria (i.e., progression of organ dysfunction or enlargement of pre-existing lesion or exaggerated inflammatory reaction and decrease in plasma HIV viral load by > 1 log copies/mL). 11, 15 All IRIS and relapse cases were reviewed and validated by two infectious diseases specialists who were experts in the field. The underlying cause of death was considered to be histoplasmosis in the presence of clinical symptoms related to histoplasmosis and with a positive direct examination result or culture of H. capsulatum within one month before death.
Statistical analysis. The current study based on specific missions of the NRCMA has been approved by the appropriate Institutional Review Board. Information was obtained anonymously and entered coded in a secured website (approved by the French commission on personal data and freedom). Statistical analysis was performed by using StataSE10 software (StataCorp, College Station, TX) and R software ( http://cran .r-project.org ). Distributions of variables were compared by using the chi-square test or Fisher's exact test for categorical variables and the Student's t -test for continuous variables.
Overall survival was the time interval between the date of diagnosis and the date of death or last follow-up. KaplanMeier estimates were used to describe survival distributions.
The log-rank test was used to compare survival distributions. Multivariate analyses were performed by using Cox proportional hazards regression model.
Histoplasmosis-related death probabilities were obtained from crude cumulative incidence estimates, which treated death from other causes as competing risk events. Cumulative incidences of death related to histoplasmosis were compared between subgroups by using the method of Fine and Gray. 16 Multivariate proportional hazards models accounting for death from other causes as a competing risk were fitted by using the same method.
RESULTS
Baseline demographic and HIV parameters during the pre-HAART and HAART eras. Among the 104 patients studied ( Table 1 ) , 40 were diagnosed during the pre-HAART era (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) and 64 during the HAART era (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) . In the second period, the proportion of women ( P = 0.04) and that of patients born in Africa ( P < 0.001) increased. The proportion of females born in Africa increased from 5% (2 of 40) to 31% (20 of 64; P = 0.001). There was a significant change in the mode of HIV transmission with a decrease in the proportion of homosexual or bisexual men and intravenous drug users and an increase in the proportion of heterosexual patients ( P < 0.001). Histoplasmosis was significantly more frequently the initial event leading to the diagnosis of HIV infection during the HAART era. Median CD4+ T cell count was similar during the two periods. All patients traveled to areas in which histoplasmosis was endemic. Geographic areas of exposure were diverse but mostly in Africa and French Guiana ( Table 1 ) Characteristics of histoplasmosis at diagnosis. Histoplasmosis was diagnosed nearly two months after the first symptoms in both periods ( Table 2 ). Clinical presentation did not differ during the two periods for more frequent clinical signs (fever, peripheral adenopathies, liver or spleen enlargement, abdominal pain, diarrhea). However, pulmonary symptoms (cough and sputum) were more frequently recorded during the pre-HAART era but the same proportion of patients had an abnormal chest radiograph. The pattern of dermatologic lesions evolved and showed a significant decrease in papules (37% versus 17%; P = 0.02). Neurologic symptoms remained scarce. Overall, histoplasmosis was disseminated in 73 (70%) of 104 patients. Biological parameters remained similar and showed only a trend towards decreased hemoglobin levels during the HAART era (9.1 ± 2.2 versus 8.3 ± 1.9 g/dL; P = 0.07). Serum alkaline phosphatase levels were increased (> 2× the upper limit of the reference value) in 43% and 39% of patients, respectively ( P > 0.05) and aspartate aminotransferase levels were increased (> 2× the upper limit of the reference value) in 32% and 55%, respectively ( P = 0.03).
Clinical severity was assessed only during the second period. Most (n = 41, 64%) patients had at least one of the severity criteria, including hypoalbuminemia (48%), a lactate dehydrogenase level > 2× the upper limit of the reference value (36%), hypotension (14%), disseminated intravascular coagulation (13%), renal insufficiency (11%), and hypoxemia (5%).
The diagnostic tools used remained similar during the two periods ( Table 3 ). More than 90% of the patients had a positive histopathologic or direct examination results and approximately 80% had a positive fungal culture. The most frequently contributive clinical specimens were bone marrow (60%), skin or mucosal specimen (39%), blood (36%), and respiratory samples (36%). Positive skin/mucosal samples were slightly more frequent during the pre-HAART era (50% and 31%; P = 0.06). There was also a trend towards an increase in the prevalence of positive blood culture (35% and 54%; P = 0.10).
Histoplasmosis-related IRIS. Seven (11%) patients diagnosed during the HAART era showed development of IRIS related to histoplasmosis ( Table 4 ). Four of them had been reported elsewhere. 11, 17 In two cases, a 51-year old woman treated with HAART and chemotherapy for Kaposi's sarcoma and a 33-year old man who had AIDS-defining toxoplasmosis and onset of HAART three weeks before IRIS, IRIS was the first manifestation of histoplasmosis. Histoplasmosis was the first manifestation of HIV infection for the five other patients. IRIS occurred 1-2 months after diagnosis of histoplasmosis in three patients. Two patients had late-onset IRIS but they had unplanned interruption of HAART, resumed HAART without medical advice 2-3 months before IRIS, and consulted a physician only when IRIS occurred. IRIS was severe in two patients: one had uveitis that finally required enucleation, and one had intestinal obstruction that required colectomy.
Outcome of 104 patients with histoplasmosis. Ninetyfive (91%) patients received antifungal drugs for at least 48 hours. Most (64%) patients received one amphotericin B formulation. Forty-seven (45%) patients received deoxycholate amphotericin B, including 38 patients subsequently switched to itraconazole. Twenty (19%) patients were prescribed liposomal amphotericin B, including 15 patients switched Median follow-up was 31.5 months (range = 0-120 months) and 41 deaths were observed. Overall mortality rate was 39% in the entire cohort. Mortality rate was higher in the pre-HAART era (hazard ratio [HR] = 0.25, 95% confidence interval [CI] = 0.13-0.48; P < 0.001) ( Figure 1 ). Death was related to histoplasmosis in 21 (51%) patients. All related deaths were observed before one year. The histoplasmosis-related mortality rate was higher during pre-HAART era than during the HAART era (HR = 0.30, 95% CI = 0.12-0.74, P = 0.009). Two (5%) patients relapsed during the pre-HAART era, and 4(6%) relapsed during the HAART era.
Factors associated with mortality. Overall mortality and histoplasmosis-related mortality were significantly associated with arterial hypotension (HR = 2.38, 95% CI =1.05-5.38, P = 0.037 and HR = 10.49, 95% CI = 2.59-42.45, P < 0.001, respectively) by univariate analysis ( Table 5 ) . Pulmonary involvement, dyspnea, cutaneous involvement, platelet count, and hemoglobin level were not associated with overall or histoplasmosis-related mortality ( Table 6 ). There was a trend towards lower mortality among patients treated with liposomal amphotericin B (HR = 0.63, 95% CI = 0.25-1.58, P = 0.38) or itraconazole alone (HR = 0.54, 95% CI = 0.21-1.34, P = 0.18) than among those treated with deoxycholate amphotericin B.
Age and diagnosis during the HAART era were independently associated with overall mortality (HR = 1.72 per 10-years increase, 95% CI = 1.17-2.54, P = 0.006 and HR = 0.19, 95% CI = 0.01-0.39, P < 0.001, respectively) and histoplasmosis-related mortality (HR = 2.16 per 10-years increase, 95% CI = 1.10-4.22, P = 0.025, and HR = 0.22, 95% CI = 0.08-0.61, P = 0.04, respectively) by multivariate analysis.
DISCUSSION
We analyzed 104 cases of proven AIDS-related histoplasmosis in metropolitan France. This study represents the largest reported cohort from a non-endemic area. 12 Histoplasmosis caused by H . capsulatum is a rare, invasive, fungal infection in France, and diagnosis is frequently delayed. All patients had traveled to a disease-endemic area, including 14% for more than 10 years before given a diagnosis of histoplasmosis, and all were strongly immunocompromised (median CD4 cell count = 15 cells/µL).
Comparison of our data concerning patients from a nonendemic area with those related to patients from North, Central, and South America is summarized in Table 5 . Our patients were characterized by a high frequency of extrapulmonary lesions (skin, adenopathy, hepatomegaly, splenomegaly). This finding could reflect a high fungal burden, a hypothesis strengthened by the high mortality rate (60%) recorded in our study during the pre-HAART era, and potentially explained by delayed diagnosis caused in part by lack of awareness of clinicians in France. An alternative hypothesis to explain the differences in clinical patterns between patients ‡ Baseline was diagnosis of acquired immunodeficiency syndrome (AIDS). AIDS was detected by histoplasmosis for all patients except patients 1 and 2 for whom IRIS was the first manifestation of histoplasmosis. Patient 1 was treated with chemotherapy and highly active anti-retroviral therapy (HAART) for Kaposi's sarcoma. Histoplasmosis-related adenopathy appeared three months after onset of HAART, when chemotherapy was stopped. Patient 2 had AIDS-defining toxoplasmosis and onset of HAART three weeks before IRIS. § These patients have been reported. 11, 17 ¶ These two patients had an unplanned interruption of HAART and became compliant again 2 months before IRIS. No immunovirologic data were available during HAART interruption. from different areas could be the implication of different, area-restricted H. capsulatum isolates. 18 This hypothesis could not be further explored in our study because of lack of storage of the clinical isolates.
Histoplasmosis caused by H. capsulatum is more frequent in AIDS patients than histoplasmosis caused by H. capsulatum var. duboisii . Less than 20 cases of AIDS-related H. duboisii histoplasmosis have been reported in the literature. 19 The two variants infect patients who have poor immunologic status. Skin lesions and adenopathies are common during both diseases. However, patients infected with H. duboisii have less hepatosplenomegaly and pulmonary involvement than patients infected with H. capsulatum ( Table 7 ) . Bone lesions appear to be suggestive of H. duboisii infection. The mortality rate is probably higher in H. capsulatum patients (39% for the H. capsulatum patients in this study and 24% for H. duboisii patients in published studies).
One-year overall mortality significantly decreased from 53% during the pre-HAART era to 22% during the HAART era among AIDS-related histoplasmosis patients from metropolitan France. Although clinical features of histoplasmosis were similar during the two periods, some significant changes occurred and could be in part responsible for improvement in survival: modification of HIV infection epidemiology in France, availability of liposomal amphotericin, and widespread use of HAART.
The typical AIDS-related histoplasmosis patient during the pre-HAART era was a homosexual/bisexual male from Europe with previously defined AIDS and one or several prior opportunistic infections. However, heterosexual women from Africa without a known history of AIDS were more frequently seen during the HAART era. The data support the conclusion that physicians should no longer assume that histoplasmosis is caused by H. duboisii in all cases originating in Africa. During the HAART era, 31% of patients were treated with liposomal amphotericin, a drug that was not previously available, which explains why only deoxycholate amphotericin B and/or itraconazole were prescribed during the first period. Because liposomal amphotericin was more effective than deoxycholate amphotericin B in reducing overall mortality after two weeks of treatment in a randomized controlled trial, 5 it was anticipated that short-term (two weeks) survival would improve during the second period. This prediction was not observed. The design of our study (a cohort study and not a therapeutic trial), and therefore the lack of standardization preclude any definitive conclusions. Finally, all patients in the second period who survived more than two weeks after diagnosis of histoplasmosis received HAART.
Treatment with HAART was started 1-3 months after onset of histoplasmosis. However, the impact of HAART on outcome of AIDS-related histoplasmosis has not been established. 20 Our data suggest that HAART had a major impact in decreasing overall mortality in AIDS patients with histoplasmosis.
Such a positive impact of HAART on late mortality has already been established for other opportunistic infections such as those with Pneumocystis jirovecii , cryptococcosis, or tuberculosis in industrialized countries. [21] [22] [23] [24] A significant decrease in early mortality had not been reported for any other opportunistic infections. 21 Patient age and the period of diagnosis were the only independent prognostic factors identified in our study. Hypoalbuminemia, disseminated intravascular coagulation, increased lactate dehydrogenase levels, renal failure, hypotension, and hypoxemia have been reported as prognostic factors 7, 10 but were not identified in our study because of the small size of the cohort and the reduced number of deaths.
Immune reconstitution inflammatory syndrome occurred in 11% of the patients during the HAART era. This incidence is similar to that identified for cryptococcosis 25 and lower than that for tuberculosis (40%) in AIDS patients who never received HAART. 26 All histoplasmosis-related IRIS patients had a dramatic increase in CD4 cell count and a decrease in HIV viral load, similar to Mycobacterium tuberculosis -related IRIS patients. 26 Severe forms requiring surgery were diagnosed in two patients. Interestingly, IRIS was the first manifestation of histoplasmosis in two patients. Such a finding is consistent with those of a retrospective study that reported that HIV patients living in French Guiana had an increased risk of histoplasmosis during the first two months after beginning HAART. 27 The IRIS cases occurred in three of the patients more than two months after the beginning of HAART. However, two patients had an unplanned interruption of HAART and became compliant again two months before IRIS, and IRIS occurred in one patient shortly after the interruption of chemotherapy for Kaposi's sarcoma.
In conclusion, overall survival after AIDS-related histoplasmosis increased in metropolitan France, a non-endemic area, during the HAART era. Because most patients came from Africa, H. capsulatum histoplasmosis should no longer be considered as American histoplasmosis, but must be considered in every febrile severely immunocompromised HIV-infected patient who had already traveled to a disease-endemic area. Immune reconstitution inflammatory syndrome occurred after HAART in up to 11% of patients and may be an indicator of histoplasmosis.
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